In this Issue  by unknown
Kidney International (2011) 80             897
http://www.kidney-international.org
© 2011 International Society of Nephrology
in  this  issue
Kidney International (2011) 80, 897. doi:10.1038/ki.2011.334
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Combined angiotensin-
converting enzyme 
inhibitors and 
angiotensin receptor 
blockers increase risk in 
end-stage renal disease
Most patients on hemodialysis require 
antihypertensive agents, and the use 
of angiotensin-converting enzyme 
inhibitors (ACEIs) and/or angioten-
sin receptor blockers (ARBs) is part 
of the standard of care. As they report 
in this issue, Chan et al. analyzed the 
roles these medications might have in 
the mortality of a very large cohort of 
patients on hemodialysis. After adjust-
ment for known cardiovascular risk 
factors, the study found no difference 
between patients started on ACEIs 
and those started on ARBs. However, 
some started on both drugs, and these 
patients had a higher risk of mortality. 
Patients started on ACEIs and another 
antihypertensive medication also 
were at an increased risk. Yet those 
started on an ARB and another (non-
ACEI) antihypertensive medication 
did not have an increased mortality. 
 See page 978.
Hemodialysis  
versus peritoneal 
dialysis in congestive 
heart failure
In their study using a large patient reg-
istry, Sens et al. compared the use of 
peritoneal dialysis versus hemodialysis 
in patients with end-stage renal disease 
who incidentally also had congestive 
heart failure. More patients were on 
hemodialysis than peritoneal dialysis 
(by a factor of 4). Those receiving peri-
toneal dialysis had a median survival of 
20 months, versus 37 months for those 
on hemodialysis. Re-analysis of the data 
using propensity scores did not change 
the conclusion. The problem is that 
these studies cannot tell us whether the 
patients were placed on one or another 
modality without prior prejudice. 
Hence, the interesting conclusion must 
remain tentative until randomized trials 
can be conducted. See page 970.
Sickle trait and dose 
of erythropoiesis-
stimulating agent
African Americans with end-stage renal 
disease appear to have a higher require-
ment for erythropoietin and other eryth-
ropoiesis-stimulating agents (ESAs) than 
similar white patients. This requirement 
may be due to a variety of nutritional, 
social, and other factors. Derebail et 
al. studied what role hemoglobino-
pathies might have in this increased 
ESA requirement. In their center, they 
found that almost 20% of their African-
American patients had hemoglobin S 
or hemoglobin C. After correcting for 
many confounders, they found that 
those with the hemoglobinopathy trait 
received almost twice the dose of ESAs 
that those with normal hemoglobin pat-
terns received. See page 992.
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